guest ::
| Home > Publications database > Long-term survival trends for primary liver and pancreatic cancers in the Nordic countries. > print |
| Home > Publications database > Long-term survival trends for primary liver and pancreatic cancers in the Nordic countries. > print |
| 001 | 182490 | ||
| 005 | 20240229145720.0 | ||
| 024 | 7 | _ | |a 10.1016/j.jhepr.2022.100602 |2 doi |
| 024 | 7 | _ | |a pmid:36352895 |2 pmid |
| 024 | 7 | _ | |a pmc:PMC9638835 |2 pmc |
| 024 | 7 | _ | |a altmetric:136634040 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2022-02685 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Hemminki, Kari |0 P:(DE-He78)19b0ec1cea271419d9fa8680e6ed6865 |b 0 |e First author |u dkfz |
| 245 | _ | _ | |a Long-term survival trends for primary liver and pancreatic cancers in the Nordic countries. |
| 260 | _ | _ | |a Amsterdam |c 2022 |b Elsevier |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1668083494_6565 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a #EA:C020# |
| 520 | _ | _ | |a Liver cancer (LC) and pancreatic cancer (PC) are often diagnosed at an advanced stage resulting in high mortality. High-quality survival data are rarely available for trend analyses over a long period.The Danish, Finnish, Norwegian, and Swedish cancer data were accessed at the NORDCAN database. We analysed relative 1- and 5-year survival trends in LC and PC between years 1970 and 2019.Relative 1-year survival in LC for Nordic men and women was about 10% in the period between 1970 and 1974, and it increased moderately by year 2000 and steeply thereafter, eventually reaching 40-50%. The patterns in 5-year survival were similar, but after the year 2000, survival in Norway and Sweden increased steeply to 23%, whereas survival in Denmark and Finland lagged behind, reaching 10% to 15%. The patterns for PC also showed rapid improvement after the year 2000, with 1-year survival reaching 30% to 40% and 5-year survival reaching 10% for Finland and 15% for Norway and Sweden. Survival was best for patients diagnosed before age 50 years, and it was worst for older patients. For both cancers the difference between 1- and 5-year survival increased with time.Survival in LC and PC improved first modestly and then steeply over the 50-year period covered. The increase in 5-year survival was less than that of 1-year survival. The survival gains were most likely the result of earlier diagnosis, improved treatment, and better organised supportive care. The challenges are to keep up these positive trends, to extend survival benefits past Year 1, and to obtain similar results in elderly patients. Primary prevention through avoidance of risk factors would reduce case numbers.Liver and pancreatic cancers are among the most lethal of all cancers. In 50 years, survival in these cancers has slowly improved, and in the past 20 years, the development has been increasingly favourable. Widespread adoption of healthy lifestyles will be key to reducing the risk of these cancers. |
| 536 | _ | _ | |a 313 - Krebsrisikofaktoren und Prävention (POF4-313) |0 G:(DE-HGF)POF4-313 |c POF4-313 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a CI5, Cancer Incidence in Five Continents |2 Other |
| 650 | _ | 7 | |a DK, Denmark |2 Other |
| 650 | _ | 7 | |a FI, Finland |2 Other |
| 650 | _ | 7 | |a Hepatocellular carcinoma |2 Other |
| 650 | _ | 7 | |a IARC, International Agency for Research on Cancer |2 Other |
| 650 | _ | 7 | |a ICD, International Classification of Diseases |2 Other |
| 650 | _ | 7 | |a ICSS, International Cancer Survival Standard |2 Other |
| 650 | _ | 7 | |a IPMN, intraductal papillary mucinous neoplasm |2 Other |
| 650 | _ | 7 | |a LC, liver cancer |2 Other |
| 650 | _ | 7 | |a Mortality |2 Other |
| 650 | _ | 7 | |a NO, Norway |2 Other |
| 650 | _ | 7 | |a PAF, population attributable fraction |2 Other |
| 650 | _ | 7 | |a PC, pancreatic cancer |2 Other |
| 650 | _ | 7 | |a Relative survival |2 Other |
| 650 | _ | 7 | |a Risk factors |2 Other |
| 650 | _ | 7 | |a SE, Sweden |2 Other |
| 650 | _ | 7 | |a Treatment |2 Other |
| 700 | 1 | _ | |a Försti, Asta |0 P:(DE-He78)f26164c08f2f14abcf31e52e13ee3696 |b 1 |u dkfz |
| 700 | 1 | _ | |a Hemminki, Otto |b 2 |
| 700 | 1 | _ | |a Liska, Vaclav |b 3 |
| 700 | 1 | _ | |a Hemminki, Akseli |b 4 |
| 773 | _ | _ | |a 10.1016/j.jhepr.2022.100602 |g Vol. 4, no. 12, p. 100602 - |0 PERI:(DE-600)2972660-8 |n 12 |p 100602 |t JHEP reports |v 4 |y 2022 |x 2589-5559 |
| 909 | C | O | |o oai:inrepo02.dkfz.de:182490 |p VDB |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 0 |6 P:(DE-He78)19b0ec1cea271419d9fa8680e6ed6865 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 1 |6 P:(DE-He78)f26164c08f2f14abcf31e52e13ee3696 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-313 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Krebsrisikofaktoren und Prävention |x 0 |
| 914 | 1 | _ | |y 2022 |
| 915 | _ | _ | |a Creative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND (No Version) |0 LIC:(DE-HGF)CCBYNCNDNV |2 V:(DE-HGF) |b DOAJ |d 2020-09-06 |
| 915 | _ | _ | |a Article Processing Charges |0 StatID:(DE-HGF)0561 |2 StatID |d 2020-09-06 |
| 915 | _ | _ | |a Fees |0 StatID:(DE-HGF)0700 |2 StatID |d 2020-09-06 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b JHEP REP : 2021 |d 2022-11-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2022-11-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2022-11-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0501 |2 StatID |b DOAJ Seal |d 2021-07-05T06:57:05Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0500 |2 StatID |b DOAJ |d 2021-07-05T06:57:05Z |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b DOAJ : Blind peer review |d 2021-07-05T06:57:05Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2022-11-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2022-11-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2022-11-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2022-11-26 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b JHEP REP : 2021 |d 2022-11-26 |
| 920 | 1 | _ | |0 I:(DE-He78)C020-20160331 |k C020 |l C020 Epidemiologie von Krebs |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)B062-20160331 |k B062 |l B062 Pädiatrische Neuroonkologie |x 1 |
| 920 | 1 | _ | |0 I:(DE-He78)HD01-20160331 |k HD01 |l DKTK HD zentral |x 2 |
| 920 | 0 | _ | |0 I:(DE-He78)C020-20160331 |k C020 |l C020 Epidemiologie von Krebs |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)C020-20160331 |
| 980 | _ | _ | |a I:(DE-He78)B062-20160331 |
| 980 | _ | _ | |a I:(DE-He78)HD01-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|